22nd Century Group launches VLN® cigarettes in 150 locations, targeting adult smokers and enhancing revenue potential.
Quiver AI Summary
22nd Century Group, Inc. announced the launch of its Pinnacle VLN® cigarette brand in approximately 150 new retail locations in the metro New York and northern New Jersey areas, aiming to reach a significant market of nearly 800,000 adult smokers. This rollout is part of the company's broader commercial growth strategy focused on its low nicotine products, which are authorized by the FDA to help reduce nicotine consumption. The expansion enhances consumer access to VLN® cigarettes and is projected to drive high-margin revenue as well as increase brand visibility in a densely populated market. CEO Larry Firestone highlighted the significance of this milestone as validation of the company's strategy and an opportunity to support health initiatives related to smoking reduction.
Potential Positives
- Launch of the VLN® product in over 150 new high-visibility store locations enhances consumer access and positions XXII to capture a significant adult-smoker market in metro New York and northern New Jersey.
- This rollout supports 22nd Century Group's broader commercial growth strategy, expanding their retail presence in a strategically important convenience retail corridor.
- The VLN® product is the first combustible cigarette authorized by the FDA for reduced nicotine consumption, which could attract health-conscious smokers and align with public health initiatives.
- CEO Larry Firestone emphasized that this distribution expansion strengthens market visibility and underscores the scalability and value of the company’s low nicotine product strategy.
Potential Negatives
- Expansion into a highly competitive market, with strong consumer traffic, may not guarantee success, increasing operational risks and potential losses if performance expectations are not met.
- Dependent on FDA-authorized claims, which could be challenged or altered, potentially impacting consumer trust and sales.
- Financial forecasts are labeled as forward-looking statements, emphasizing uncertainty in meeting anticipated results, which could affect investor confidence.
FAQ
What is the significance of the VLN® product launch?
The VLN® product launch expands 22nd Century Group's retail presence and targets a large adult-smoker market in metro New York and northern New Jersey.
How does VLN® help smokers?
VLN® offers a low-nicotine cigarette designed to help smokers reduce their nicotine consumption and potentially quit smoking.
Where will VLN® products be available?
VLN® products will be available in nearly 150 high-visibility store locations primarily in the metro New York area and northern New Jersey.
What authorization has VLN® received from the FDA?
VLN® low nicotine cigarettes were authorized by the FDA as the first combustible cigarettes to help reduce nicotine consumption.
What does 22nd Century Group focus on?
22nd Century Group focuses on tobacco harm reduction and nicotine reduction through innovative products like VLN® cigarettes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XXII Revenue
$XXII had revenues of $4.1M in Q1 2026.
You can track XXII financials on Quiver Quantitative's XXII stock page.
You can access data on XXII stock through the Quiver Quantitative API.
$XXII Hedge Fund Activity
We have seen 16 institutional investors add shares of $XXII stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC removed 143,617 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $110,585
- ANSON FUNDS MANAGEMENT LP added 44,334 shares (+677.2%) to their portfolio in Q4 2025, for an estimated $34,137
- UBS GROUP AG added 3,296 shares (+430.3%) to their portfolio in Q1 2026, for an estimated $7,284
- VANGUARD GROUP INC added 3,175 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,444
- GEODE CAPITAL MANAGEMENT, LLC added 3,100 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,387
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,671 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,286
- VIRTU FINANCIAL LLC removed 1,231 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,720
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
VLN ® Product Launch in Over 150 New High-Visibility Store Locations Positions XXII to Introduce VLN ® to New Consumers and Potentially Capture a Large Adult-Smoker Market, Accelerate High-Margin Revenue
MOCKSVILLE, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced that shipments are expected to commence of its Pinnacle VLN ® cigarette brand for sale through one of the nation’s largest purveyors of cigarettes in the US, with distribution expanding to almost 150 stores concentrated in the metro New York area and northern New Jersey.
This new rollout marks the first of a series of significant steps forward in 22nd Century Group’s broader commercial growth strategy and further expands the Company’s Pinnacle VLN ® retail presence in one of the most densely populated, high-traffic, and strategically important convenience retail corridors in the United States. By increasing distribution across metro New York and northern New Jersey, the Company is broadening consumer access to its VLN-focused product platform while creating a meaningful opportunity to drive consumer acquisition, incremental high-margin revenue and enhance low nicotine combustible cigarette category awareness.
The Pinnacle launch enters a market corridor representing an estimated nearly 800,000 adult cigarette smokers, underscoring the scale of the commercial opportunity in the rollout region. VLN ® products are tailored to align with health and wellness initiatives of state and local governments, who continue to invest in smoking prevention and cessation efforts, including programs such as NYS Quits, NYC Quits, and the New Jersey Quitline, highlighting the continued importance of innovation and differentiation in tobacco products.
Larry Firestone, Chief Executive Officer of 22nd Century Group, said, “This expanded distribution of our Pinnacle VLN ® brand is an important milestone for 22nd Century Group and a strong validation of our commercial strategy. Launching in metro New York and northern New Jersey gives us exposure in a highly active retail corridor with exceptional market density, strong consumer traffic, and meaningful revenue potential.”
Firestone continued, “We believe this rollout meaningfully strengthens the visibility of the 22 nd Century Group’s position in the marketplace. It demonstrates the scalability of our platform, the value of our VLN ® strategy, and our ability to execute in major metropolitan markets. Most importantly, it positions us to expand consumer awareness, accelerate revenue growth, expand margins, and continue advancing toward cash positive operations.”
FDA Authorization and Scientific Foundation
22 nd Century VLN ® low nicotine combustible cigarettes were authorized in December 2021, making them the first and still the only combustible cigarettes authorized by the U.S. Food and Drug Administration specifically to help reduce nicotine consumption.
Decades of independent clinical research and peer-reviewed studies—evaluated as part of the FDA’s Modified Risk Tobacco Product (MRTP) authorization process—demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine.
FDA-authorized VLN ® claims include:
- “95% less nicotine”
- “Helps reduce your nicotine consumption”
- “Greatly reduces your nicotine consumption”
- “Helps you smoke less”
About 22nd Century Group, Inc.
22 nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption.
Our Technology is Tobacco
Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our-high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.
Our Products
We created our flagship product, the VLN ® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN ® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.
VLN ® and Helps You Smoke Less ® are registered trademarks of 22nd Century Limited LLC.
Learn more at xxiicentury.com , on X (formerly Twitter) , on LinkedIn , and on YouTube .
Learn more about VLN ® at tryvln.com .
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive authorization or approval for new products, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
[email protected]
214-597-8200